This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SANOFI : Sanofi Reaches New Milestone In Fight Against Malaria: 300 Million ASAQ Treatments Delivered In Africa

Stocks in this article: SAN

PARIS, April 25, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced on World Malaria Day that 300 million treatments of anti-malarial ASAQ Winthrop ® have been delivered in Africa since the medication became available in 2007.

"Beyond the therapeutic and industrial innovation of this medication, the real success of this project is in the social innovation," said Dr. Robert Sebbag, Vice President, Access to Medicines, Sanofi. " By forgoing a patent on this treatment and committing to a tiered pricing model, with prices which can reach "no profit-no loss" levels for the public sector and major international health organizations, Sanofi and the Drugs for Neglected Diseases initiative (DNDi) took a bold step that has improved access to antimalarial treatments."

In line with the WHO guidelines, which recommend the use of Artemisinin-based Combination Therapy (ACT) for the treatment of malaria, ASAQ Winthrop ® combines artesunate and amodiaquine in a fixed-dose combination, enabling better adherence to treatment and reducing the risk of resistance. ASAQ Winthrop ® was developed through an innovative partnership with DND i, an independent not-for-profit foundation.

Manufactured by Sanofi at its Casablanca plant in Morocco, ASAQ Winthrop ® is now registered in 33 countries, 30 of them in Africa. It is easy to use (once-daily dosing) and is available at a price of less than US$1 for adults and US$0.50 for children, for a full three-day treatment regimen.

Through partnerships with African National Malaria Control Programs, Sanofi is working with local experts and other non-governmental organizations on educational programs and materials aimed at fighting malaria on all fronts, from prevention to diagnosis and treatment. One such program, the "Schoolchildren Against Malaria" initiative has reached more than 3.6 million children across nine African countries through games, theatre competitions and related TV programs.

Malaria is the world's most common and deadliest parasitic disease. According to the latest data released by the World Health Organization (WHO) in December 2013, 207 million cases and 627,000 deaths were reported in 2012, 90% of them in Africa. Most deaths occur among children living in Africa, where a child dies every minute from malaria. Beyond being a major public health issue, malaria also weighs heavily on the finances of affected families and the economies of endemic countries. Early diagnosis and treatment of malaria can help reduce disease severity and transmission, and prevent death.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,389.97 -288.73 -1.63%
S&P 500 2,033.74 -23.35 -1.14%
NASDAQ 4,694.6530 -77.11 -1.62%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs